ACRS vs. ASRT, RVPH, ETON, BYSI, QTTB, MIST, CMRX, LFVN, BTAI, and LPTX
Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Assertio (ASRT), Reviva Pharmaceuticals (RVPH), Eton Pharmaceuticals (ETON), BeyondSpring (BYSI), Q32 Bio (QTTB), Milestone Pharmaceuticals (MIST), Chimerix (CMRX), LifeVantage (LFVN), BioXcel Therapeutics (BTAI), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical preparations" industry.
Assertio (NASDAQ:ASRT) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
In the previous week, Aclaris Therapeutics had 1 more articles in the media than Assertio. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 1 mentions for Assertio. Assertio's average media sentiment score of 0.84 beat Aclaris Therapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.
Assertio has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.
49.0% of Assertio shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 7.9% of Assertio shares are held by company insiders. Comparatively, 5.5% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Assertio currently has a consensus price target of $5.50, suggesting a potential upside of 564.09%. Aclaris Therapeutics has a consensus price target of $22.25, suggesting a potential upside of 1,754.17%. Given Assertio's higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Assertio.
Aclaris Therapeutics received 274 more outperform votes than Assertio when rated by MarketBeat users. Likewise, 66.96% of users gave Aclaris Therapeutics an outperform vote while only 58.86% of users gave Assertio an outperform vote.
Aclaris Therapeutics has lower revenue, but higher earnings than Assertio. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks.
Assertio has a net margin of -218.28% compared to Assertio's net margin of -283.15%. Aclaris Therapeutics' return on equity of 6.30% beat Assertio's return on equity.
Summary
Aclaris Therapeutics beats Assertio on 9 of the 17 factors compared between the two stocks.
Get Aclaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclaris Therapeutics Competitors List
Related Companies and Tools
